PLAUR and Familial prostate cancer: The design and implementation of theranostic approaches combining uPAR-targeted therapeutic and non-invasive imaging modalities, such as positron emission tomography (PET), magnetic resonance (MRI), or near-infrared (NIR) fluorescence imaging, are currently underway and hold clinical potential for significantly improving patient management and disease outcomes, as evidenced by the encouraging results achieved for prostate cancer in recent years [27,28].